Results 201 to 210 of about 22,935 (284)

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8552-8559, September 2026.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

What Works in Type 2 Diabetes: Intermittent Fasting or Calorie Restriction or Both? [PDF]

Indian J Endocrinol Metab
Nagendra L, Bhattacharya S, Kapoor N, Kalra S.   +3 more
europepmc   +1 more source

Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active‐Controlled Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8602-8612, September 2026.
ABSTRACT Aim To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. Materials and Methods This randomized, Phase III, non‐inferiority study included adults with obesity or overweight with or without comorbidities from ...
Unnikrishnan Ambika Gopalakrishnan, Ameya Joshi, Harish Kumar, Richa Giri, Sanjiv Maheshwari, Valluri Satya Prasad, Jitendra Shukla, Rekha M. Chowdaiah, Nutan Kumar Agrawal, Yogesh Rasal, Banshidhar Sahoo, Shweta Bhandari, Ambanna Gowda, Uday Phadke, Pravin Supe, Niranjan Pathak, Ambrish Chandrappa, Ashutosh Sonawane, Yash Bahulikar, Amit Bhaskar, Arunkumar Radhakrishnan, Priyanka Yadav, Sucheta Pandit, Supriya Sonowal, Dipak Patil, Pravin Ghadge, Suyog Mehta   +26 more
wiley   +1 more source

GLP-1RAs: antidiabetic drug crossover-new hope for chronic inflammatory airway diseases. [PDF]

Respir Res
Chen Y, Shen Y, Shen H, Liu Z.
europepmc   +1 more source

A case of maturity‐onset diabetes of the young with a pathogenic HNF1A variant and a coexisting NEUROD1 variant

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1457-1466, September 2026.
ABSTRACT Aims/Introduction Maturity‐onset diabetes of the young (MODY) accounts for at least 1%–5% of diabetes cases and is usually caused by single gene variants. Accurate diagnosis of MODY is important for effective management, especially in young individuals who are lean and lack islet autoantibodies.
Tomofumi Takayoshi, Yushi Hirota, Kenji Sugawara, Aki Sugano, Mika Ohta, Takehito Takeuchi, Akane Yamamoto, Wataru Satake, Yutaka Takaoka, Wataru Ogawa   +9 more
wiley   +1 more source

Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes. [PDF]

Diabetologia
Zhang X, Yang A, Wu H, Lau ESH, Shi M, Fan B, Chow E, Kong APS, Chan JCN, Ma RCW, Luk AOY.   +10 more
europepmc   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1489-1498, September 2026.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

A Five-Year Study on Treatment Changes in Hypoglycemia-Associated Medications: Towards Personalized Diabetes Management. [PDF]

J Pers Med
Asiri A, Cahyaningsih I, de Vos S, Bos JHJ, Schuiling-Veninga CCM, Hak E, Mubarik S, Denig P, Taxis K.   +8 more
europepmc   +1 more source

Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1533-1537, September 2026.
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike, Yoko Irie, Yuji Doi, Ryosuke Kemmotsu, Moe Kusushita, Yasuna Sakai, Tomonori Okita, Hiroyuki Sho, Ryoko Inui, Yukiko Tabuchi, Tetsuyuki Yasuda   +10 more
wiley   +1 more source

Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data.

Lancet Prim Care
Jansz TT, McGovern AP, Young KG, Dinsdale MM, Cardoso P, Shields BM, Hattersley AT, Jones AG, Pearson ER, Bingham C, Oram RA, Dennis JM.   +11 more
europepmc   +1 more source